Results 11 to 20 of about 15,728 (206)
Italian Journal of Medicine, 2013 Antiplatelet drugs are the cornerstone of treatment for patiens with Acute Coronary Syndromes (ACS) undergoing percutaneous coronary intervention. Clopidogrel and aspirin improve longterm vascular clinical outcomes in these patients and have become a ...
Gianluca Airoldi, Mauro Campanini
doaj +10 more sources
Prasugrel inhibits TLR7-driven autoimmunity in systemic lupus erythematosus by acetylating cGAS [PDF]
Nature CommunicationsSystemic lupus erythematosus (SLE) has a complex, multifactorial etiology, which contributes to a lack of definitive cure and limited treatment efficacy. Here, we report that cyclic GMP-AMP synthase (cGAS) is significantly activated in SLE patients.
Zeng-Lin Guo +34 more
doaj +2 more sources
The efficacy and safety of prasugrel in acute coronary syndrome: a propensity-matched Korean cohort study focused on age and weight of patients [PDF]
BMC Cardiovascular DisordersBackground The clinical benefits of prasugrel compared to clopidogrel in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are well established.
Sang Hyun Kim +11 more
doaj +2 more sources
Cardiovascular Diabetology, 2020 Background Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in
William A. E. Parker +8 more
doaj +2 more sources
Circulation Journal, 2023 BACKGROUND P2Y12 inhibitor monotherapy without aspirin immediately after percutaneous coronary intervention (PCI) has not been tested in East Asian patients, so in this study we aimed to assess the safety and feasibility of reduced dose (3.75 mg/day ...
T. Muramatsu +25 more
semanticscholar +1 more source
Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. [PDF]
PLoS ONE, 2013 Administration of the thienopyridine P2Y12 receptor antagonist, clopidogrel, increased the erosive arthritis induced by peptidoglycan polysaccharide (PG-PS) in rats or by injection of the arthritogenic K/BxN serum in mice. To determine if the detrimental
Analia E Garcia +5 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 AimsWhether early or delayed dual antiplatelet therapy initiation is better in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is unclear. We assessed the evidence for comparing the efficacy and safety of early vs. delayed P2Y12
Lourdes Vicent +10 more
doaj +1 more source
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
PLoS ONE, 2022 BackgroundTriple antithrombotic therapy, including dual antiplatelet therapy and oral anticoagulant (OAC), is recommended for a short-term period after percutaneous coronary intervention (PCI) in patients requiring anticoagulation therapy. The purpose of
Hideki Kitahara +5 more
doaj +1 more source